Detalles de la búsqueda
1.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med;
389(20): 1839-1850, 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870973
2.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med;
389(22): 2039-2051, 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870976
3.
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
Cancer;
130(4): 541-552, 2024 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37843249
4.
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
N Engl J Med;
383(13): 1207-1217, 2020 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955176
5.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med;
383(9): 813-824, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32846060
6.
Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance.
Mod Pathol;
36(7): 100184, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37054974
7.
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.
Future Oncol;
19(33): 2213-2225, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37589131
8.
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Future Oncol;
19(1): 61-75, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36656302
9.
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
N Engl J Med;
381(21): 2020-2031, 2019 11 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31562796
10.
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
Eur J Immunol;
51(4): 956-964, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506525
11.
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.
Invest New Drugs;
40(2): 265-273, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34973117
12.
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Oncology;
100(4): 228-237, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35196661
13.
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Cancer;
127(16): 3019-3028, 2021 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33826761
14.
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Cancer;
127(9): 1407-1416, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33434335
15.
MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC.
Eur J Immunol;
50(11): 1810-1819, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510574
16.
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
BMC Cancer;
21(1): 802, 2021 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253172
17.
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.
Future Oncol;
17(18): 2395-2408, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33855865
18.
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future Oncol;
17(7): 763-773, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150799
19.
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations.
Int J Clin Oncol;
26(5): 841-850, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33783657
20.
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model.
Nanomedicine;
37: 102415, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34174421